Royalty Revenue was Innoviva’s largest product and service line in fiscal 2025, bringing in $236.48M of $411.33M (57%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Royalty Revenue | $311.65M | $238.85M | $241.73M | $236.48M | ||||||
| Royalty Revenue From A Related Party | — | — | — | — | ||||||
| Giapreza | $14.21M | $41.29M | $55.04M | $73.61M | ||||||
| Xacduro | — | $2.00M | $21.07M | $74.39M | ||||||
| Xerava | $5.48M | $17.32M | $21.39M | $23.52M | ||||||
| License & Other Revenue | — | $11.00M | $19.49M | $2.72M | ||||||
| Revenue From Collaborative Arrangements | — | — | — | — | ||||||
| Revenue From Collaborative Arrangements From A Related Party | — | — | — | — | ||||||
| Zevtera | — | — | — | $610.00K | ||||||
| Total | $331.34M | $310.46M | $358.71M | $411.33M |
Innoviva brought in $411.33M from its six product and service lines in fiscal 2025, the year ended December 31, 2025. Innoviva regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $358.71M. Royalty Revenue was the largest at $236.48M (57.5%), ahead of Xacduro at $74.39M (18.1%) and Giapreza at $73.61M (17.9%). The other three lines brought in $26.85M combined.
Compared with fiscal 2024, Xacduro grew fastest, up 253.1% to $74.39M, while Royalty Revenue fell the most, down 2.2% to $236.48M.
Innoviva began breaking out Xacduro in fiscal 2023, License & Other Revenue in fiscal 2023 and Zevtera in fiscal 2025.
Long-Acting Beta Agonist (Laba) Collaboration was Innoviva’s largest revenue line in fiscal 2012, bringing in $3.63M of $5.61M (65%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2012 |
|---|---|
| Long-Acting Beta Agonist (Laba) Collaboration | $3.63M |
| 2004 Strategic Alliance | $1.98M |
| Total | $5.61M |
Innoviva brought in $5.61M from its two revenue lines in fiscal 2012, the year ended December 31, 2012. Long-Acting Beta Agonist (Laba) Collaboration was the largest at $3.63M (64.7%), ahead of 2004 Strategic Alliance at $1.98M (35.3%).
Innoviva (INVA) reports its revenue by product and service and by collaborative arrangement and arrangement other than collaborative. In fiscal 2025, Royalty Revenue was its largest product and service line, bringing in $236.48M (57.5% of the total), followed by Xacduro at $74.39M (18.1%).
Royalty Revenue was Innoviva's largest product and service line in fiscal 2025, bringing in $236.48M, or 57.5% of the $411.33M total across its six product and service lines.
Long-Acting Beta Agonist (Laba) Collaboration was Innoviva's largest revenue line in fiscal 2012, bringing in $3.63M, or 64.7% of the $5.61M total across its two revenue lines.
Every figure comes from Innoviva's annual financial filings, as reported. Each line keeps the name Innoviva gives it, and years follow its fiscal calendar.
Innoviva's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.